Guo Kangxiao, Tang Yuan, Yang Tao, Yan Yongwang
National Engineering Laboratory for Rice and By-Product Deep Processing, College of Food Science and Engineering, Central South University of Forestry and Technology, Changsha, China.
Department of Pharmacy, ChangSha Health Vocational College, Changsha, Hunan, China.
Front Cell Infect Microbiol. 2025 Mar 6;15:1556915. doi: 10.3389/fcimb.2025.1556915. eCollection 2025.
To investigate the correlation between the treatment of spleen deficiency constipation and the typical brain and intestinal peptides.
A total of 18 male Kunming mice were randomly divided into three treatment groups (n = 6): normal group (CC), model group (CM), and Massa Medicata Fermentata intervention group (CG). CM and CG were used to establish a spleen deficiency constipation mouse model. After the model was finished, CG was infused with 0.15 g/mL Massa Medicata Fermentata water infusion at a dose of 4 g/(kg·day), twice a day, at 0.4 mL. An equal amount of distilled water was infused in CC and CM for 7 days. The body weight and fecal water content of the mice were monitored during the modeling. Following the intervention, 16S rRNA amplicon sequencing was used to analyze changes in the microflora in the intestinal contents, and serum substance P (SP), vasoactive intestinal peptide (VIP), and calcitonin gene-related peptide (CGRP) levels were determined via ELISA.
The modeling had no significant effect on the weight of the mice, the water content of the mice's feces was greatly reduced, and the feces were dry and hard. Constipation caused by spleen deficiency can lead to a decrease in serum SP and an increase in VIP and CGRP. After treatment with Massa Medicata Fermentata, SP, VIP, and CGRP all changed. Intestinal microbiota diversity of mice with spleen deficiency constipation, and the dominant microbiota and characteristic microbiota changed, indicating that the intestinal microbiota was unbalanced. After the intervention of Massa Medicata Fermentata, the intestinal microbiota diversity of spleen deficiency constipation mice increased; the dominant microbiota became Arthromitus, , unclassified Bacilli, , , , , and ; and the characteristic microbiota became Arthromitus. Through the analysis of characteristic microbiota and serum SP, VIP, and CGRP levels, was found to be positively correlated with SP and negatively correlated with VIP, and were negatively correlated with SP, Arthromitus was negatively correlated with CGRP, and Arthromitus were negatively correlated with VIP, and Arthromitus was negatively correlated with CGRP.
Massa Medicata Fermentata can affect the secretion of short-chain fatty acids in the intestine by altering the microecological environment of the intestine, then affect the secretion of serum peptides in mice, and alleviate the spleen deficiency constipation.
探讨脾虚便秘治疗与典型脑肠肽之间的相关性。
将18只雄性昆明小鼠随机分为三个治疗组（n = 6）：正常组（CC）、模型组（CM）和六神曲干预组（CG）。CM组和CG组用于建立脾虚便秘小鼠模型。造模完成后，CG组按4 g/(kg·天)的剂量给予0.15 g/mL六神曲水煎液灌胃，每日2次，每次0.4 mL。CC组和CM组给予等量蒸馏水，连续7天。造模期间监测小鼠体重和粪便含水量。干预后，采用16S rRNA扩增子测序分析肠道内容物中微生物群落的变化，并通过酶联免疫吸附测定法测定血清P物质（SP）、血管活性肠肽（VIP）和降钙素基因相关肽（CGRP）水平。
造模对小鼠体重无显著影响，但小鼠粪便含水量大幅降低，粪便干结。脾虚所致便秘可导致血清SP降低，VIP和CGRP升高。六神曲治疗后，SP、VIP和CGRP均发生变化。脾虚便秘小鼠肠道微生物群落多样性及优势微生物群落和特征微生物群落发生改变，提示肠道微生物群落失衡。六神曲干预后，脾虚便秘小鼠肠道微生物群落多样性增加；优势微生物群落变为节杆菌属、未分类芽孢杆菌属等；特征微生物群落变为节杆菌属。通过对特征微生物群落与血清SP、VIP和CGRP水平的分析，发现某菌与SP呈正相关，与VIP呈负相关，另一些菌与SP呈负相关，节杆菌属与CGRP呈负相关，某些节杆菌属与VIP呈负相关，节杆菌属与CGRP呈负相关。
六神曲可通过改变肠道微生态环境影响肠道短链脂肪酸分泌，进而影响小鼠血清肽分泌，缓解脾虚便秘。
